Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2007-06-12
2007-06-12
Steadman, David J. (Department: 1656)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S130100, C530S387900
Reexamination Certificate
active
11207142
ABSTRACT:
The present invention provides crystalline forms and three-dimensional atomic structure coordinates of Synagis Fab. The present invention further provides methods of using such three-dimensional atomic structure coordinates for designing and identifying Synagis binding agents. The present invention also provides machine readable media embedded with the three-dimensional atomic structure coordinates of Synagis Fab and methods of using them.
REFERENCES:
patent: 5994511 (1999-11-01), Lowman et al.
patent: 6113898 (2000-09-01), Anderson et al.
patent: 6129914 (2000-10-01), Weiner et al.
patent: 6955717 (2005-10-01), Johnson et al.
patent: WO 96/40252 (1996-12-01), None
patent: WO 00/61618 (2000-10-01), None
patent: 02/13583 (2003-04-01), None
Giege et al. Crystallogenesis of Biological Macromolecules: Facts and Perspectives. Acta Cryst., (1994) D50. pp. 339-350.
Drenth, J. “Principles of Protein X-Ray Crystallography”, 2nd Edition, 1999 Springer-Verlag New York Inc., Chapter 1, pp. 1-21.
Weber, P.C. Overview of Crystallization Methods. Methods in Enzymology, 1997, vol. 276, pp. 13-22.
Cudney, R. Protein Crystallization and Dumb Luck. Rigaku Journal. 1999. vol. 16, No. 1, pp. 1-7.
Hampton Research , 1991 “Crystal Screen Users Guide,”.
Johnson et al. 1997 “Development of a Humanized Monoclonal Antibody (MEDI-493) With Potent In Vitro and In Vivo Activity Against Respiratory Syncytial Virus,”The Journal of Infectious Diseases, 176:1215-24.
Meissner et al., 1999 “Immunoprophylaxis With Palivizumab, A Humanized Respiratory Syncytial Virus Monoclonal Antibody, For Prevention of Respiratory Syncytial Virus Infection In High Risk Infants: A Consensus Opinion,”Pediatr Infect Dis. J,18:223-31.
Meng et al. 1992 “Automated Docking with Grid-Based Energy Evaluation,”Journal of Computational Chemistry, 2(13):505-524.
Braden Bradford
Johnson Leslie S.
Bowie State University
Jones Day
Medimmune Inc.
Noakes Suzanne M.
Steadman David J.
LandOfFree
Crystals and structure of Synagis Fab does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystals and structure of Synagis Fab, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystals and structure of Synagis Fab will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3883046